Navigation Links
BioConvergence® Presents Case Study on Temperature Controlled Pharmaceutical Products
Date:10/19/2013

Bloomington, Indiana (PRWEB) October 18, 2013

BioConvergence team members Désirée Valentine and Travis Hudson presented their newest case study (including outcomes of yielding a 99.7 percent excursion-free shipping rate) at the 11th Annual Cold Chain & Temperature Management Global Forum in Chicago, IL earlier this month.

The conference, led by IQPC, focused on shipping regulations, strategies, and trends within the life sciences industry, with special emphasis on maintaining product integrity through temperature management.

“There is plenty of evidence that suggests that a product’s temperature (and the associated fluctuations) can have profound impacts on a product’s stability, and therefore, its therapeutic effectiveness,” relates Valentine, Senior Supply Chain Manager at BioConvergence. “Because of this, BioConvergence is committed to keeping our clients’ products within appropriate temperature conditions while at our facility and throughout transit. This year, our team has implemented key changes that have resulted in improved metrics and additional value to clients. In presenting this data at IQPC, we hope that others will utilize this case study to realize similar results and promote improvements throughout the pharmaceutical supply chain.”

These improvements, as were discussed in Valentine and Hudson’s presentation, are as follows:

  •     Yielded a 99.7 percent excursion-free rate
  •     Decreased Average Days in Transit by over 1 day per shipment
  •     Reduced Days in Transit (50% reduction in “Delivery Past Qualification” time)
  •     Improved coordination, both internally and externally
  •     Established processes for continual improvement moving forward

When asked how BioConvergence achieved these results, Hudson, Associate Process Engineer at BioConvergence, responded, “We began by having a clear picture of the results we wanted to see: improvements to key performance indicators and partnerships, as well as reductions to excursion rates. Next, we began an in-depth analysis of our existing processes and flagged five specific root causes that were interfering with outcomes. After strategically addressing each of these items, we began to see improvements in our metrics. This process has become the standard at BioC in promoting continual improvements.”

In addition to presenting this case study, Valentine and Hudson also led a roundtable discussion during the conference entitled, “How to Create Value through Designing and Implementing a Shipping Lane Qualification for High Value Pharmaceutical Products.”

To learn more about the framework BioConvergence developed, download the full case study at http://www.bioc.us/iqpc.

About BioConvergence

BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, BioC has over 50 employees with more than four centuries’ worth of combined experience in the pharmaceutical industry. BioC’s unique E-Transparency® System provides transparency and flexibility to its clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.bioc.us.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11245946.htm.


'/>"/>
Source: PRWeb
Copyright2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioConvergence®, Contract Manufacturing Organization for the Life Sciences Industry, Announces New Board of Directors
2. CEO of BioConvergence® Receives Women Excel Bloomington Award for Outstanding Leadership and Service
3. BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment
4. BioConvergence® Launches New Blog Aimed at Exploring Best Practices of Pharmaceutical and Biotechnology Industries
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
7. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
8. San Francisco Business Times Presents: Richmond! Your Home Front for Business
9. Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century
10. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
11. Clinovo Presents Its Paper ‘Cloud for Clinical Trials’ at Society for Clinical Data Management (SCDM) Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):